An artificial intelligence is now allowed legally to participate in clinical decisions over prescription renewals.The approval, made in the US state of Utah, is a global first, the company behind the technology, Doctronic, told The BMJ.In a pilot programme, Doctronic’s AI platform will decide if patients should have their prescriptions renewed for treatment for chronic conditions.Doctronic was rolled out in December 2025 and is run through the Utah Department of Commerce’s Office of Artificial Intelligence Policy.Officials say they expect the technology to speed up prescription renewals and reduce costs. The pilot will assess safety, timeliness, and adherence.Adam Oskowitz, Doctronic cofounder and an associate professor of surgery at the University of California in San Francisco, pointed to medication non-compliance as “one of the largest drivers of poor health outcomes and preventable healthcare costs,” responsible for hundreds of billions in avoidable medical expenses annually.“Improving access to drug renewals will directly impact this…